Safety and efficacy of a 1-year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfecta

Journal of Pediatric Endocrinology and Metabolism

Volumn 25, Issue 5-6, 2012, Pages 485-491

  Barros, Elizabete Ribeiro ^a   Saraiva, Gabriela L ^a   De Oliveira, Telma Palomo ^a   Lazaretti Castro, Marise ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

BMD; Efficacy; Osteogenesis imperfecta; Pamidronate; Zoledronic acid

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; CREATININE; PAMIDRONIC ACID; PARATHYROID HORMONE; PHOSPHORUS; ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE;

ADOLESCENT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BONE DENSITOMETRY; CALCIUM BLOOD LEVEL; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; EPIGASTRIC PAIN; FEMALE; FEVER; FOLLOW UP; FRACTURE; HEADACHE; HUMAN; LUMBAR SPINE; MALE; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; OSTEOGENESIS IMPERFECTA; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRESCHOOL CHILD; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RASH; SCHOOL CHILD; VOMITING; BONE DENSITY; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; INFANT; TREATMENT OUTCOME;

ADOLESCENT; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CHILD; CHILD, PRESCHOOL; DIPHOSPHONATES; FEMALE; FRACTURES, BONE; HUMANS; IMIDAZOLES; INFANT; MALE; OSTEOGENESIS IMPERFECTA; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84865615359     PISSN: 0334018X     EISSN: 21910251     Source Type: Journal    
DOI: 10.1515/jpem-2012-0016     Document Type: Article

References (31)

1. Smith R. Osteogenesis imperfecta, non-accidental injury, and temporary brittle bone disease. Arch Dis Child 1995;72: 169-71.
2. McCarthy EA, Raggio CL, Hossack MD, Miller EA, Jain S, et al. Alendronate treatment for infants with osteogenesis imperfecta: demonstration of efficacy in a mouse model. Pediatr Res 2002;52:660-70.
3. Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet 1979;16:101-16.
4. Glorieux FH, Rauch F, Plotkin H, Ward L, Travers R, et al. Type V osteogenesis imperfecta: a new form of brittle bone disease. J Bone Miner Res 2000;15:1650-8.
5. Glorieux FH, Ward LM, Rauch F, Lalic L, Roughley PJ, et al. Osteogenesis imperfecta type VI: a form of brittle bone disease with a mineralization defect. J Bone Miner Res 2002;17: 30-8.
6. Ward LM, Rauch F, Travers R, Chabot G, Azouz EM, et al. Osteogenesis imperfecta type VII: an autosomal recessive form of brittle bone disease. Bone 2002;31:12-8.
7. Labuda M, Morissette J, Ward LM, Rauch F, Lalic L, et al. Osteogenesis imperfecta type VII maps to the short arm of chromosome 3. Bone 2002;31:19-25.
8. Baron R, Gertner JM, Lang R, Vignery A. Increased bone turnover with decreased bone formation by osteoblasts in children with osteogenesis imperfecta tarda. Pediatr Res 1983;17: 204-7.
9. Rauch F, Travers R, Parfitt AM, Glorieux FH. Static and dynamic bone histomorphometry in children with osteogenesis imperfecta. Bone 2000;26:581-9.
10. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, et al. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 1998;339:947-52.
11. Plotkin H, Rauch F, Bishop NJ, Montpetit K, Ruck-Gibis J, et al. Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. J Clin Endocrinol Metab 2000;85:1846-50.
12. Lee YS, Low SL, Lim LA, Loke KY. Cyclic pamidronate infusion improves bone mineralisation and reduces fracture incidence in osteogenesis imperfecta. Eur J Pediatr 2001;160: 641-4.
13. Rauch F, Travers R, Plotkin H, Glorieux FH. The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. J Clin Invest 2002;110:1293-9.
14. Rauch F, Plotkin H, Travers R, Zeitlin L, Glorieux FH. Osteogenesis imperfecta types I, III, and IV: effect of pamidronate therapy on bone and mineral metabolism. J Clin Endocrinol Metab 2003;88:986-92.
15. DiMeglio LA, Ford L, McClintock C, Peacock M. Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta. Bone 2004;35:1038-45.
16. Choi JH, Shin YL, Yoo HW. Short-term efficacy of monthly pamidronate infusion in patients with osteogenesis imperfecta. J Korean Med Sci 2007;22:209-12.
17. Hogler W, Yap F, Little D, Ambler G, McQuade M, et al. Shortterm safety assessment in the use of intravenous zoledronic acid in children. J Pediatr 2004;145:701-4.
18. Reid IR. Zoledronate: efficacy and safety. J Bone Miner Res 2006;21(Suppl 2):P83-7.
19. Vuorimies I, Toiviainen-Salo S, Herro M, Makitie O. Zoledronic acid treatment in children with osteogenesis imperfecta. Horm Res Paediatr 2011;75:346-53.
20. Munns CF, Rajab MH, Hong J, Briody J, Hogler W, et al. Acute phase response and mineral status following low dose intravenous zoledronic acid in children. Bone 2007;41: 366-70.
21. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809-22.
22. Negrin D. Growth calculation 2.01, 2000. Available at: http://growthcalc.chip.org.
23. Zeitlin L, Rauch R, Travers R, Munnus C, Glorieux FH. The effect of cyclical intravenous pamidronate in children and adolescent with osteogenesis imperfecta type V. Bone 2006;38: 13-2026.
24. Brown JJ, Ramalingam L, Zacharin MR. Bisphosphonateassociated osteonecrosis of the jaw: does it occur in children ? Clin Endocrinol (Oxf) 2008;68:863-7.
25. Panigrahi I, Das RR, Sharda S, Marwaha RK, Khandelwal N. Response to zolendronic acid in children with type II osteogenesis imperfect. J Bone Miner Metab 2010;28: 451-5.
26. Glorieux FH, Bishop N, Bober M, Brain CE, Devogelaer J, et al. Intravenous zoledronic acid compared to intravenous pamidronate in children with severe osteogenesis imperfecta. Calcif Tissue Int 2008;82:S85.
27. Astrom E, Soderhall S. Beneficial effect of bisphosphonate during five years of treatment of severe osteogenesis imperfecta. Acta Paediatr 1998;87:64-8.
28. Rauch F, Plotkin H, Travers R, Glorieux FH. Is bone resorption increased in children with osteogenesis imperfecta (OI) ? Bone 1998;52(Suppl 462).
29. Lage AZ, Brandao CA, Mendes JR, Huayllas MK, Liberman B, et al. High degree of discordance between three-dimensional and two-dimensional lumbar spine bone mineral density in Turner ' s syndrome. J Clin Densitom 2005;8:461-6.
30. Whyte MP, Wenkert D, Clements KL, McAlister WH, Mumm S. Bisphosphonate-induced osteopetrosis. N Engl J Med 2003;349:457-63.
31. Van den Wyngaert T, Huizing MT, Vermorken JB. Osteonecrosis of the jaw related to the use of bisphosphonates. Curr Opin Oncol 2007;19:315-22.